Madrigal Pharmaceuticals Inc MDGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDGL is a good fit for your portfolio.
News
-
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
-
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
-
Madrigal Pharmaceuticals Announces Proposed Public Offering
-
Madrigal's stock surges as FDA approves first drug for liver disease MASH
-
Madrigal Shares Leap Premarket on First FDA NASH Green Light
-
Madrigal Pharmaceuticals Wins Accelerated Approval for Rezdiffra From FDA
Trading Information
- Previous Close Price
- $222.26
- Day Range
- $206.03–224.68
- 52-Week Range
- $119.76–322.67
- Bid/Ask
- $150.00 / $216.80
- Market Cap
- $4.45 Bil
- Volume/Avg
- 625,155 / 612,831
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 376
- Website
- http://www.madrigalpharma.com
Comparables
Valuation
|
Metric
|
MDGL
|
PLRX
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.90 | 1.63 | 12.65 |
Price/Sales | — | 477.92 | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
MDGL
PLRX
CBAY
Financial Strength
|
Metric
|
MDGL
|
PLRX
|
CBAY
|
|---|---|---|---|
Quick Ratio | 5.35 | 17.43 | 10.70 |
Current Ratio | 5.38 | 17.72 | 10.96 |
Interest Coverage | −29.93 | −145.34 | −5.27 |
Quick Ratio
MDGL
PLRX
CBAY
Profitability
|
Metric
|
MDGL
|
PLRX
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −86.33% | −22.68% | −30.06% |
Return on Equity (Normalized) | −184.32% | −24.50% | −51.97% |
Return on Invested Capital (Normalized) | −122.82% | −28.46% | −30.87% |
Return on Assets
MDGL
PLRX
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mzlcjlfpzm | Zglj | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ysqdgjxv | Yssmfw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mwzyhkbb | Fhkyt | $98.1 Bil | |
MRNA
| Moderna Inc | Ynbtplftc | Tyd | $39.1 Bil | |
ARGX
| argenx SE ADR | Vvdsxfvgq | Nqz | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Yqtjmffmd | Bzp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fydyvrpv | Pgxyrl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tgrlkbqng | Wvzsgs | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fmyqbqpx | Nlhdgcv | $12.5 Bil | |
INCY
| Incyte Corp | Svthpmws | Mhfnpg | $11.9 Bil |